• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

作者信息

Lieberman Jeffrey A

机构信息

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA.

出版信息

Arch Gen Psychiatry. 2006 Oct;63(10):1069-72. doi: 10.1001/archpsyc.63.10.1069.

DOI:10.1001/archpsyc.63.10.1069
PMID:17015808
Abstract
摘要

相似文献

1
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).抗精神病药物的比较疗效。对《精神分裂症研究中最新抗精神病药物的成本效用》（CUtLASS 1）和《干预有效性临床抗精神病药物试验》（CATIE）的评论。
Arch Gen Psychiatry. 2006 Oct;63(10):1069-72. doi: 10.1001/archpsyc.63.10.1069.
2
Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).结果、成本与政策警示。对《精神分裂症最新抗精神病药物的成本效用研究（CUtLASS 1）》的评论
Arch Gen Psychiatry. 2006 Oct;63(10):1074-6. doi: 10.1001/archpsyc.63.10.1074.
3
First- and second-generation antipsychotics: learning from CUtLASS and CATIE.第一代和第二代抗精神病药物：从CUtLASS和CATIE研究中汲取经验。
Arch Gen Psychiatry. 2007 Aug;64(8):977-8; author reply 979-80. doi: 10.1001/archpsyc.64.8.977.
4
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.抗精神病药与精神分裂症：从疗效和有效性到临床决策。
Can J Psychiatry. 2010 Mar;55(3):117-25. doi: 10.1177/070674371005500302.
5
The costs of drugs for schizophrenia.精神分裂症药物的成本。
Am J Psychiatry. 2006 Dec;163(12):2029-31. doi: 10.1176/ajp.2006.163.12.2029.
6
Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.氯氮平治疗难治性精神分裂症的药物经济学评价：一项成本效用分析。
Can J Clin Pharmacol. 2001 Winter;8(4):199-206.
7
The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.精神分裂症的CATIE和CUtLASS研究：结果及对临床医生的启示
CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.
8
Switch or stay?改变还是维持？
Am J Psychiatry. 2006 Dec;163(12):2032-3. doi: 10.1176/ajp.2006.163.12.2032.
9
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?用于治疗精神分裂症的第二代抗精神病药物：我们能否解决这一冲突？
Psychol Med. 2009 Oct;39(10):1591-602. doi: 10.1017/S0033291709005455. Epub 2009 Apr 1.
10
The NIMH-CATIE Schizophrenia Study: what did we learn?美国国立精神卫生研究所-抗精神病药物干预有效性临床试验精神分裂症研究：我们学到了什么？
Am J Psychiatry. 2011 Aug;168(8):770-5. doi: 10.1176/appi.ajp.2011.11010039.

引用本文的文献

1
Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.针对精神病的认知行为疗法：一项卫生技术评估。
Ont Health Technol Assess Ser. 2018 Oct 24;18(5):1-141. eCollection 2018.
2
Olanzapine-Induced Neutropenia.奥氮平所致中性粒细胞减少症。
Ment Illn. 2015 Jun 23;7(1):5871. doi: 10.4081/mi.2015.5871. eCollection 2015 Feb 24.
3
Adapting SugarWatch to manage metabolic syndrome in a partial hospitalization program: a feasibility study.在部分住院计划中采用SugarWatch管理代谢综合征：一项可行性研究。
Hawaii J Med Public Health. 2015 Mar;74(3):81-6.
4
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.抗精神病药物奥氮平与肠道微生物群相互作用，导致小鼠体重增加。
PLoS One. 2014 Dec 15;9(12):e115225. doi: 10.1371/journal.pone.0115225. eCollection 2014.
5
Atypical antipsychotic usage among Asian Americans and Pacific Islanders.亚裔美国人和太平洋岛民中使用非典型抗精神病药物的情况。
Hawaii J Med Public Health. 2014 Sep;73(9):288-91.
6
Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?抗精神分裂症药物的疗效比较：真实世界试验给我们带来了哪些启示？
CNS Drugs. 2012 Jun 1;26(6):491-508. doi: 10.2165/11632020-000000000-00000.
7
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.超越多巴胺受体：治疗精神分裂症的新型治疗靶点。
Dialogues Clin Neurosci. 2010;12(3):359-82. doi: 10.31887/DCNS.2010.12.3/jcoyle.
8
Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.氯氮平对急性和慢性间断性苯环利定诱导的 5 选择连续反应时任务中表现缺陷的分离作用。
Psychopharmacology (Berl). 2011 Feb;213(4):681-95. doi: 10.1007/s00213-010-2020-7. Epub 2010 Sep 29.
9
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.5-羟色胺转运体基因多态性 5-HTTLPR 和 RS25531 与精神分裂症或神经认知无关联。
Am J Med Genet B Neuropsychiatr Genet. 2010 Jul;153B(5):1115-7. doi: 10.1002/ajmg.b.31077.
10
Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.慢性 NT69L 有力地预防了药物引起的前脉冲抑制中断，而不会导致耐受。
Behav Brain Res. 2010 Feb 11;207(1):118-24. doi: 10.1016/j.bbr.2009.09.044. Epub 2009 Oct 2.